# Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

> **NCT00925132** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Iowa** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Temozolomide, Decitabine, Panobinostat

## Key facts

- **NCT ID:** NCT00925132
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2014-11
- **Final completion:** 2016-12
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Change in the number of approved drugs for metastatic melanoma
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925132, "Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00925132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*